Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma

High Grade Lymphomas CD20 Positive Clinical Trial

Status Completed

Clinical Trial Summary

R-CHOP with doxorubicin is the standard first line treatment of high grade non-Hodgkin's lymphoma. In order to avoid central venous system insertion and reduce hospitalization time in elderly patients, we developed an oral chemotherapy treatment: " OROCIEP"trial.

Nineteen patients were enrolled and 127 chemotherapy cycles were available for toxicities. The estimated two-years overall survival was 74%. The main haematological toxicity was neutropenia.

This study is still ongoing to confirm recommended dose of oral anthracycline.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• High Grade Lymphomas CD20 Positive
• Lymphoma
• Lymphoma, Non-Hodgkin

• NCT number: NCT01958996
• Study type: Interventional
• Source: Poitiers University Hospital
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 2009
• Completion date: December 31, 2016